Akers Biosciences, Inc. Heparin PF4 Rapid Test in Puerto Rico
April 10 2017 - 1:00AM
RNS Non-Regulatory
TIDMAKR
Akers Biosciences, Inc.
10 April 2017
10 April 2017
Akers Biosciences
to Commercialize Heparin PF4 Rapid Test in Puerto Rico
Large New U.S-aligned Market Opportunity
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the
"Company" or "Akers Bio"), a developer of rapid health information
technologies, announces that the Company has begun marketing its
rapid test for heparin-induced thrombocytopenia ("HIT") to the
large number of hospital facilities in Puerto Rico as an extension
of the Company's strategy to accelerate U.S. sales of its flagship
product. The Company believes Puerto Rico represents a large new
market opportunity which is closely aligned to the U.S. and has
more than 60 potential hospital targets.
Akers Bio has appointed a specialist independent outsourced
sales group to represent the test in Puerto Rico as well as a
leading channel partner with established logistical access in the
region.
Akers Bio's flagship PIFA Heparin/PF4 Rapid Assay and PIFA PLUSS
PF4 tests were designed to quickly determine at - or near - the
point-of-care if a patient being treated with the widely used blood
thinner heparin may be developing HIT. This clinical syndrome
reverses heparin's intended therapeutic effect and transforms it
into a clotting agent. Patients suffering HIT are at risk of
developing limb- and life-threatening complications, so the timely
test result provided by the Company's Heparin/PF4 devices is
paramount to effective and cost-efficient clinical decision
making.
John J. Gormally, Chief Executive Officer of Akers Bio,
commented: "Puerto Rico is a strategically important market for
Akers Bio to target as an extension of our U.S. sales strategy.
There are some 64 potential hospital customers on the island and we
believe the opportunity to enable those prospective customers to
generate significant cost savings through the timely diagnosis of
HIT will be very attractive."
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
John J. Gormally, Chief Executive Officer
Raymond F. Akers, Jr. PhD, Vice Chairman
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7830 9704
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFSVSAIDIID
(END) Dow Jones Newswires
April 10, 2017 02:00 ET (06:00 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2024 to May 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From May 2023 to May 2024